Pharmaceuticals, Biotechnology and Life Sciences
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March…
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05…
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) — Tilray Brands Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), and…
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) — eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] – a pioneer of AI-engineered enzymes…
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay…
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC…
– RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary…
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from…
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable,…